Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Viral Inactivation Market Worth $5.1 Billion by 2025 | CAGR: 12.5%: Grand View Research, Inc.

Grand View Research,Inc.
Posted on: 06 Sep 17
Viral Inactivation Market Worth $5.1 Billion by 2025 | CAGR: 12.5%: Grand View Research, Inc.

PR Newswire

SAN FRANCISCO, September 6, 2017

SAN FRANCISCO, September 6, 2017 /PRNewswire/ --

The global viral inactivation market is anticipated to reach USD 5.1 billion by 2025, growing at a CAGR of 12.5%, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the market.

Browse full research report with TOC on " Viral Inactivation Market Analysis By Product, By Application (Vaccines, Therapeutics, Stem Cell Products, Blood Products, Tissue Products, Cellular, Gene Therapy), By End-use, And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com/industry-analysis/viral-inactivation-market

Further Key Findings From the Study Suggest:  

  • Kits and reagents held the largest share owing to increasing usage of consumables
  • Vaccines and therapeutics held the largest share, on the basis of application, and is expected to be the fastest growing segment due to the increased demand for biologics
  • The services segment is anticipated to grow at the fastest rate due to increase in the number of pharmaceutical CROs globally
  • North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases
  • The Asia Pacific region is expected to flourish during the forecast period owing to healthcare reforms and untapped market opportunities in the pharmaceutical industry

Browse related reports by Grand View Research: 


Grand View Research has segmented the global viral inactivation market on the basis of product, application, end use, and region: 

  • Viral Inactivation Product Outlook (Revenue, USD Million; 2014 - 2025) 
    • Kits and Reagents
    • Systems
    • Services
  • Viral Inactivation Application Outlook (Revenue, USD Million; 2014 - 2025) 
    • Vaccines and Therapeutics
    • Stem Cell Products
    • Blood Tissue/Tissue Products
    • Blood and Blood Products
    • Cellular and Gene Therapy
  • Viral Inactivation End-use Outlook (Revenue, USD Million; 2014 - 2025) 
    • Pharmaceutical and Biopharmaceutical Companies
    • CROs
    • Academic and Research Institutes
    • Others 
  • Viral Inactivation Regional Outlook (Revenue, USD Million; 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa
      • Saudi Arabia

Read Our Blog By Grand View Research : http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com


SOURCE Grand View Research, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 06/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.